N/A N=120 Microbiological Evaluation of the Ocular Flora Before Cataract Surgery
Disorders of the Eye Following Cataract Surgery
Primary: Positive Culture in Subjects Scheduled for Cataract Surgery — 87 subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
N/A N=200 Preoperative Cognitive Screening of Elderly Surgical Patients
Cognitive Impairment
Primary: Number of Patients With Probable Cognitive Impairment — 23; 22 Participants
N/A N=80 Quatera 700 vs. Centurion
Cataract
Primary: Central Corneal Thickness — 572.8; 565.6 microns
Phase 4 N=105 Sedation Methods During Cataract Surgery
Phacoemulsification · Cataract
Primary: Eye Mobility During Surgery (See Link to Study Protocol for Scale) — 1.39; 1.41; 1.31 units on a scale
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
N/A N=50 Clinical Comparison of Length of Cataract Procedures With Zeiss Lumera Versus Older Zeiss Microscope
Cataract
Primary: Improvement in Operating Room Efficiencies During Cataract Surgery With the Use of the New Lumera Operating Microscope Versus an Older Zeiss Model Operating Scope…
N/A N=84 Conventional Surgery vs. Verion/VerifEye
Cataract · Astigmatism
Primary: Residual Refractive Cylinder — 0.28; 0.33 Diopters
N/A N=34 Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery
Blepharitis · Dry Eye Syndrome
Primary: Mean Change in Total Meibomian Gland Score — 12.8; 1.9 Change in Meibomian Gland Score
N/A N=15 Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines
Cataract Surgery
Primary: Number of Eyes With Stable IOP — 16; 14 Eyes
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
N/A N=108 Next Generation Cataract Surgery Study
Cataract
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Anterior Segment Surgical Functionality Perform Per the Intended Use as Defined in Protocol Section…
N/A N=150 Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
Cataract
Primary: IOL A-constant at 3 Months at Each Site — 119.23; 119.18; 118.86; 118.93 unitless
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
N/A N=400 Clinical Evaluation of a New Viscoelastic for Cataract Surgery
Cataract
Primary: Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively — 10.6; 7.6 percentage of participants
N/A N=1,045 Using Behavioral Economics to Reduce Low-Value Care
Pre-Operative Testing for Cataract Surgery
Primary: Pre-Operative Testing Change — 87.4; 85.0; 86.1; 85.4 Percentage of patients with orders
N/A N=40 Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
Cataracts
Primary: Change in Ln(Bacterial Colony Count) From Pre-antibiotic Administration to Post Study Medication Swabs — -0.14; -0.52 Ln(bacterial colony count)
Phase 4 N=126 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
Cataracts
Primary: Peak Aqueous Penetration — 688.87; 67.64; 447.1 ng/ml
Phase 4 N=126 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Cataracts
Primary: Aqueous PGE2 Inhibition — 288.7; 320.4; 224.8 pg/ml
Phase 2 N=30 Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
Phase 4 N=60 In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery
Cataract
Primary: Mean Anterior Chamber Cell/Flare Score — 1.06; 1.15 Units on a scale
Phase 1 N=4 Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Rubeosis Iridis · Proliferative Diabetic Retinopathy
Primary: Adverse Event (AE) — 0 participants
N/A N=94 Femtosecond Laser Assisted Keratotomies for the Management of Corneal Astigmatism
Astigmatism · Cataract
Primary: Keratometric Correction Index — 0.51 index
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
N/A N=203 Postoperative Cognitive Dysfunction as Geriatric Syndrome
Cognitive Dysfunction
Primary: Postoperative Cognitive Dysfunction - Results of MMSE Before Operation — 79; 43; 37; 5 Participants — p=<0.0001
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 3 N=60 Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery
Cataract
Primary: Deviation From Intended Capsulotomy Diameter — 26.8; 339.1 μm
N/A N=204 A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal
Dry Eye Syndromes
Primary: Percentage of Patients With a Presence of Matrix Metalloproteinase-9 (MMP-9) in the Study Eye — 36.2 percentage of participants